October 2020 Product News

Express Scripts Covers Rhofade on the National Preferred Formulary

EPI Health, LLC, announces that Rhofade (oxymetazoline hydrochloride) cream 1% is now covered on the Express Scripts National Preferred Formulary, providing more access to this rosacea therapy. Rhofade is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. For more information, visit www.rhofade.com.

MC2 Therapeutics and EPI Health to Collaborate on Wynzora Cream

MC2 Therapeutics announces a Collaboration Agreement with EPI Health, LLC, on the commercialization of Wynzora cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) in the United States. Wynzora cream was approved by the US Food and Drug Administration in July 2020 for the topical treatment of plaque psoriasis in adults. MC2 Therapeutics retains full ownership of Wynzora cream under the Collaboration Agreement, and MC2 Therapeutics and EPI Health will utilize their combined resources to make Wynzora cream a leading patient-preferred topical treatment of psoriasis in the United States. EPI Health will utilize its commercial infrastructure to promote and sell Wynzora cream in return of a share of net sales. For more information, visit www.wynzora.com.

Positive Phase 3 Results for Tapinarof Cream for Plaque Psoriasis

Dermavant Sciences, Inc, reports positive results from PSOARING 1 (N=510) and PSOARING 2 (N=515), two identical, multicenter, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream 1% for the treatment of plaque psoriasis in adults. In both trials, tapinarof cream demonstrated highly statistically significant improvement in PASI 75 (psoriasis area and severity index) from baseline at week 12 (P<.0001). In addition, up to 80% of patients achieved a 1-grade or higher improvement in physician global assessment across both studies. Following completion and findings of the ongoing long-term extension study, Dermavant expects to file a New Drug Application with the US Food and Drug Administration in 2021. For more information, visit www.dermavant.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at [email protected].

Express Scripts Covers Rhofade on the National Preferred Formulary

EPI Health, LLC, announces that Rhofade (oxymetazoline hydrochloride) cream 1% is now covered on the Express Scripts National Preferred Formulary, providing more access to this rosacea therapy. Rhofade is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. For more information, visit www.rhofade.com.

MC2 Therapeutics and EPI Health to Collaborate on Wynzora Cream

MC2 Therapeutics announces a Collaboration Agreement with EPI Health, LLC, on the commercialization of Wynzora cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) in the United States. Wynzora cream was approved by the US Food and Drug Administration in July 2020 for the topical treatment of plaque psoriasis in adults. MC2 Therapeutics retains full ownership of Wynzora cream under the Collaboration Agreement, and MC2 Therapeutics and EPI Health will utilize their combined resources to make Wynzora cream a leading patient-preferred topical treatment of psoriasis in the United States. EPI Health will utilize its commercial infrastructure to promote and sell Wynzora cream in return of a share of net sales. For more information, visit www.wynzora.com.

Positive Phase 3 Results for Tapinarof Cream for Plaque Psoriasis

Dermavant Sciences, Inc, reports positive results from PSOARING 1 (N=510) and PSOARING 2 (N=515), two identical, multicenter, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream 1% for the treatment of plaque psoriasis in adults. In both trials, tapinarof cream demonstrated highly statistically significant improvement in PASI 75 (psoriasis area and severity index) from baseline at week 12 (P<.0001). In addition, up to 80% of patients achieved a 1-grade or higher improvement in physician global assessment across both studies. Following completion and findings of the ongoing long-term extension study, Dermavant expects to file a New Drug Application with the US Food and Drug Administration in 2021. For more information, visit www.dermavant.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at [email protected].

Express Scripts Covers Rhofade on the National Preferred Formulary

EPI Health, LLC, announces that Rhofade (oxymetazoline hydrochloride) cream 1% is now covered on the Express Scripts National Preferred Formulary, providing more access to this rosacea therapy. Rhofade is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. For more information, visit www.rhofade.com.

MC2 Therapeutics and EPI Health to Collaborate on Wynzora Cream

MC2 Therapeutics announces a Collaboration Agreement with EPI Health, LLC, on the commercialization of Wynzora cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) in the United States. Wynzora cream was approved by the US Food and Drug Administration in July 2020 for the topical treatment of plaque psoriasis in adults. MC2 Therapeutics retains full ownership of Wynzora cream under the Collaboration Agreement, and MC2 Therapeutics and EPI Health will utilize their combined resources to make Wynzora cream a leading patient-preferred topical treatment of psoriasis in the United States. EPI Health will utilize its commercial infrastructure to promote and sell Wynzora cream in return of a share of net sales. For more information, visit www.wynzora.com.

Positive Phase 3 Results for Tapinarof Cream for Plaque Psoriasis

Dermavant Sciences, Inc, reports positive results from PSOARING 1 (N=510) and PSOARING 2 (N=515), two identical, multicenter, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream 1% for the treatment of plaque psoriasis in adults. In both trials, tapinarof cream demonstrated highly statistically significant improvement in PASI 75 (psoriasis area and severity index) from baseline at week 12 (P<.0001). In addition, up to 80% of patients achieved a 1-grade or higher improvement in physician global assessment across both studies. Following completion and findings of the ongoing long-term extension study, Dermavant expects to file a New Drug Application with the US Food and Drug Administration in 2021. For more information, visit www.dermavant.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at [email protected].